PPARD and metabolic syndrome: The results of these studiessuggest that sooner or later high-affinity PPARδ synthetic drugs which uniquelytarget multiple components of the metabolic syndrome, including obesity,insulin resistance, hyperglycemia, dyslipidemia, and atherosclerosis will enterthe market.